State Of Wyoming Fate Therapeutics Inc Transaction History

State Of Wyoming

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$1.65 - $3.94 $132,399 - $316,153	80,242 Added 562.75%	94,501 $353,000
Q3 2023 Nov 14, 2023	BUY	$2.02 - $5.04 $28,803 - $71,865	14,259 New	14,259 $30,000
Q2 2022 Aug 15, 2022	SELL	$17.78 - $42.39 $89,113 - $212,458	-5,012 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$29.67 - $60.28 $50,409 - $102,415	1,699 Added 51.28%	5,012 $194,000
Q4 2021 Feb 11, 2022	BUY	$47.84 - $64.34 $31,430 - $42,271	657 Added 24.74%	3,313 $194,000
Q3 2021 Feb 11, 2022	SELL	$59.27 - $95.73 $91,749 - $148,190	-1,548 Reduced 36.82%	2,656 $157,000
Q2 2021 Feb 11, 2022	BUY	$67.25 - $92.52 $175,724 - $241,754	2,613 Added 164.24%	4,204 $365,000
Q1 2021 Feb 08, 2022	BUY	$72.16 - $117.4 $114,806 - $186,783	1,591 New	1,591 $131,000

175

115M

53.7K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $222M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of State Of Wyoming, based on Form 13F filings with the SEC.

Stay updated on State Of Wyoming with notifications on news.